Skip to Content

Brain and Spine Tumors Clinical Trials

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained High-Grade Gliomas
Aims: The purpose of this study is to assess the use of a yellow, fluorescent dye in combination with a specialized microscope during brain surgery for the removal of a specific type of tumor called a high-grade glioma. Objectives include measuring patient outcomes and measuring the extent of tumor removal.
Principal Investigator: Julian Bailes, MD
NorthShore Project Number:
EH13-331
Sponsor:
NorthShore University HealthSystem
Contact:
Please call 847.570.4224 with questions regarding the study.
Open to Enrollment:
Yes

Compassionate Use of ABT-414 for the Treatment of Glioblastoma Multiforme
Aims: The purpose of this study is to provide the drug currently being studied in an ongoing research study to patients who do not meet the criteria to participate in the main study.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH16-225
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

A Study of Exploratory Biomarkers in EGFR-Amplified Patient-Derived Xenograft (PDX) Models from Subjects with Glioblastoma Multiforme (GBM) Clinical Study Protocol F15-712
Aims: The purpose of this study is to collect tumor tissue from patients who will receive ABT-414 on the Compassionate Use protocol for use in pre-clinical tumor models.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH17-148
Contact: Call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide
Aims: This is a Phase I study that examines the rate of dose-limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation).
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-083
Contact: Call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)
Aims: This study will evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects in participants with epidermal growth factor receptor-amplified glioblastoma who are being treated with depatuxizumab mafodotin (ABT-414). The study will include 2 phases during the treatment period: chemoradiation therapy (radiation plus temozolomide [RT/TMZ]) and adjuvant therapy (TMZ). All participants will receive depatuxizumab mafodotin during both phases of the treatment period plus 1 of 3 prophylactic ophthalmologic treatments (standard steroids, standard steroids with vasoconstrictors and cold compress, and enhanced steroids with vasoconstrictors and cooling compress).
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-096
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

A randomized, Double-blind, Phase II Trial of Surgery, Radiation Theray Plus Temozolomide and Pembroliumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Aims: The purpose of this study is to find out if adding immunotherapy (pembrolizumab) with or without a vaccine (HSPPC-96) to standard of care treatment for GBM improves survival of newly diagnosed GBM subjects. The standard treatment for GBM consists of surgery to remove the brain tumor, radiation and chemotherapy (temozolomide).
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-383
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Aims:
The purpose of this Phase III study is to finally attain a clear answer to the long-standing question of which treatment route leads to the best clinical outcome for patients with newly diagnosed WHO grade II meningioma. Subjects will be randomly assigned into one of two groups: Group 1 will be observed following surgery and Group 2 will receive radiation therapy following surgery.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-270
Contact: Call 847-570-2025 with questions regarding the study
Open to Enrollment: Yes